Loading…
Loading…
EQUITY / NYSE · XNYS
Annovis Bio, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.15 USD · -2.5424%
Observed: Oct 2, 2026, 9:27 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 1.18 USD · Volume 644,366
20 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -14,377,712 USD | -6,271,453 USD | — |
| Net income | -14,820,815 USD | -6,220,058 USD | — |
| Cash and cash equivalents | 18,728,945 USD | — | — |
| Total liabilities | 26,291,709 USD | — | — |
| Total equity | -4,254,618 USD | 18,330,447 USD | -123.21% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 18,728,945 USD | — | — | 19,532,338 USD | 19,532,338 USD | 15,286,399 USD | — | — |
| Net incomeIncome statement | -14,820,815 USD | -32,427,198 USD | -17,606,382 USD | — | -28,854,197 USD | -7,262,658 USD | -19,019,785 USD | -6,220,058 USD |
| Operating profitIncome statement | -14,377,712 USD | -32,389,895 USD | — | — | -29,695,258 USD | -7,434,975 USD | -19,989,109 USD | -6,271,453 USD |
| Total assetsBalance sheet | 22,037,091 USD | — | — | 21,081,625 USD | 21,081,625 USD | 17,188,961 USD | — | — |
| Total equityBalance sheet | -4,254,618 USD | — | 3,126,058 USD | 16,851,250 USD | 16,851,250 USD | 13,156,164 USD | — | 18,330,447 USD |
| Total liabilitiesBalance sheet | 26,291,709 USD | — | — | 4,230,375 USD | 4,230,375 USD | 4,032,797 USD | — | — |
| Financing cash flowCash flow statement | — | 30,121,851 USD | — | — | 34,600,125 USD | — | 21,427,151 USD | — |
| Operating cash flowCash flow statement | — | -30,925,244 USD | — | — | -25,619,703 USD | — | -16,692,668 USD | — |
| RevenueIncome statement | — | 0 USD | — | — | 0 USD | — | 0 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/13/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.